{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE310nnn/GSE310768/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310768"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Endothelial AGO1 Deficiency Reduces Breast Cancer Burden in Mice","description":"Endothelial cells are crucial in cancer development and progression, in part through tumor angiogenesis and immune modulation. As a key component of RNA-induced silencing complex, Argonaute 1 (AGO1) protein has been shown to regulate tumor biology. However, its role in ECs within the tumor microenvironment remains undefined. In this study, we investigated the effects of EC-conditional AGO1 knockout (EC-AGO1-KO) on tumor vascularization and immune regulation in a mouse xenograft breast cancer model. EC-AGO1-KO developed significantly reduced tumor burden when compared to their wild-type littermates. The tumor suppression was accompanied by lower tumor vascularization and stronger immune infiltration. Histological and single cell RNA sequencing analysis revealed that tumors in the EC-AGO1-KO mice exhibited increased CD8⁺ T cells and macrophages, reflecting a pro-immunostimulatory microenvironment. In vitro experiments show that EC-AGO1-knockdown (AGO1-KD) conditioned media suppresses breast cancer cell migration, attendant with the downregulation of C-X-C chemokine receptor type 4 (CXCR4) and upregulation of RUNX1 Partner Transcriptional Co-Repressor 1 (RUNX1T1). These findings suggest that EC-AGO1 plays a crucial role in regulating tumor angiogenesis and immune cell infiltration, thereby influencing tumor progression. Targeting EC AGO1 may offer a novel therapeutic strategy for disrupting tumor vascularization while enhancing anti-tumor immunity.","dates":{"publication":"2026/06/18"},"accession":"GSE310768","cross_references":{"GSM":["GSM9308565","GSM9308564","GSM9308566","GSM9308558","GSM9308557","GSM9308559","GSM9308561","GSM9308560","GSM9308563","GSM9308562"],"GPL":["24247","34328"],"GSE":["310768"],"taxon":["Mus musculus"],"PMID":["[42286210]"]}}